Eli Lilly (NYSE:LLY) saw a notable 10% increase in its stock price over the last month, driven by several important events.

Clinical trial results found that a majority of patients with atopic dermatitis who were treated with Ebgylss achieved ...

Eli Lilly (LLY) stock in focus as eczema therapy Ebglyss lead to complete skin clearance in 50% of subjects in a long-term ...

After scoring a long-awaited FDA approval last fall, Eli Lilly has launched a consumer-facing campaign to get the word out ...

New results show Eli Lilly (LLY) and Company’s Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic ...

Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

Ebglyss (lebrikizumab-lbkz) is a prescription drug used to treat atopic dermatitis in certain situations. Ebglyss comes as a liquid solution that you inject under your skin. Ebglyss is used in ...

Almirall SA (LBTSF) reports a robust 10.2% net sales increase and exceeds EBITDA projections, driven by key products Ilumetri and EBGLYSS.

Feetures, America's #1 running sock, is dedicated to supporting athletes of all ages and promoting the importance of being ...